Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI 46 PS Ratio is 1.57 as of Jul. 22, 2026, which is 99% below its 10-year median of 116.06. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.56 (Significantly Undervalued). Among 952 Drug Manufacturers companies, ODI Pharma AB ranks better than 62.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ODI Pharma AB's share price is kr2.54.
ODI Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.62. Hence, ODI Pharma AB's PS Ratio for today is 1.57.
Good Sign:
ODI Pharma AB stock PS Ratio (=1.42) is close to 10-year low of 1.39.
The historical rank and industry rank for ODI Pharma AB's PS Ratio or its related term are showing as below:
XSAT:ODI'
s PS Ratio Range Over the Past 10 Years
Min: 1.39 Med: 116.06 Max: 695.84
Current: 1.57
During the past 7 years, ODI Pharma AB's highest PS Ratio was 695.84. The lowest was 1.39. And the median was 116.06.
XSAT:ODI's PS Ratio is ranked better than 62.92% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs XSAT:ODI: 1.57
During the past 12 months, the average Revenue per Share Growth Rate of ODI Pharma AB was 134.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 100.40% per year.
During the past 7 years, ODI Pharma AB's highest 3-Year average Revenue per Share Growth Rate was 100.40% per year. The lowest was 100.40% per year. And the median was 100.40% per year.
Back to Basics: PS Ratio
ODI Pharma AB (XSAT:ODI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ODI Pharma AB PS Ratio Related Terms
ODI Pharma AB PS Ratio Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ODI Pharma AB's Share Price of today is kr2.54. ODI Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.62.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ODI Pharma AB (XSAT:ODI) has a PS Ratio of 1.57 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ODI Pharma AB and its competitors. This is 99% below median its historical median of 116.06. Over the past decade, ODI Pharma AB's PS Ratio has ranged from 1.39 to 695.84. According to the industry distribution chart, ODI Pharma AB ranks #353 out of 952 companies in the Drug Manufacturers industry, placing it in the top 37.1%.
Is ODI Pharma AB's PS Ratio too high?
ODI Pharma AB's current PS Ratio of 1.57 is 99% below median its 10-year median of 116.06. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 695.84. The Drug Manufacturers industry median PS Ratio is 2.29. ODI Pharma AB's value of 1.57 is 31.4% below this industry median. Based on the distribution chart, ODI Pharma AB ranks #353 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #353 out of 952 companies for PS Ratio. This puts ODI Pharma AB in the upper half of its industry. The industry median PS Ratio is 2.29. ODI Pharma AB's value of 1.57 is 31.4% below this benchmark. Historically, ODI Pharma AB's own PS Ratio has ranged from 1.39 to 695.84 over the past decade. While the company's 10-year median is 116.06 vs. the industry median of 2.29, ODI Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ODI Pharma AB's current PS Ratio of 1.57 is 31.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current PS Ratio is 1.57, which is 99% below median its own 10-year median of 116.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.56, compared to a current price of kr2.54 — trading 73.4% below its estimated fair value. The current PS Ratio is 1.57, which is 99% below median its 10-year median of 116.06 and 31.4% below the Drug Manufacturers industry median of 2.29. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current PS Ratio is 1.57 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.54 is trading 73.4% below its estimated GF Value™ of kr9.56.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
PS Ratio: 1.57 (99% below median its 10-year median of 116.06)
GF Value™: kr9.56 vs. price of kr2.54 (73.4% below fair value)
Industry Position: 31.4% below the Drug Manufacturers median (#353 of 952)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
